Michelle A. Baron
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michelle A. Baron has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Julio Rosenstock
University of Texas Southwestern Medical Center Dallas Texas USA
2 shared publications Lise Kjems
Intarcia Therapeutics, Inc., Boston, MA
2 shared publicationsPrakash Prabhakar
Intarcia Therapeutics, Inc., Boston, MA
2 shared publications- Robert R. Henry
Center for Metabolic Research, VA San Diego Healthcare System, San Diego, CA University of California, San Diego, La Jolla, CA
2 shared publications Douglas Logan
Medpace Clinical Pharmacology Unit, Cincinnati, Ohio
1 shared publicationDouglas S. Denham
Clinical Trials of Texas, Inc., San Antonio, TX
1 shared publication
Latest Publications
- Open Access
- 2 December 2022
- Published by Open Library of the Humanities in Zygon: Journal of Religion and Science
- Vol. 57 (4)
Theology and Science in the Thought of Ian Barbour: A Thomistic Evaluation for the Catholic Doctrine of Creation. By Joseph R.Laracy. New York: Peter Lang Publishing, 2021. 346 pages. $70.57. (Hardcover).
- 2 December 2022
- Published by Open Library of the Humanities in Zygon: Journal of Religion and Science
- Vol. 57 (4)
Open AccessTheology and Science in the Thought of Ian Barbour: A Thomistic Evaluation for the Catholic Doctrine of Creation. By Joseph R.Laracy. New York: Peter Lang Publishing, 2021. 346 pages. $70.57. (Hardcover).
- 4 January 2018
- Published by American Diabetes Association in Diabetes Care
- Vol. 41 (3) , 613-619
Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study
OBJECTIVE ITCA 650 is a subdermal osmotic mini-pump that continuously delivers exenatide subcutaneously for 3–6 months. The efficacy, safety, and tolerability of ITCA 650 added to diet and exercise alone or combined with metformin, sulfonylurea, or thiazolidinedione monotherapy or a combination of these drugs was evaluated in poorly controlled patients with type 2 diabetes (T2D) who were ineligible for participation in a placebo-controlled study (FREEDOM-1) because of severe hyperglycemia (HbA1c >10% [86 mmol/mol]). RESEARCH DESIGN AND METHODS This 39-week, open-label, phase 3 trial enrolled patients aged 18–80 years with HbA1c >10% to ≤12% (86–108 mmol/mol) and BMI 25–45 kg/m2. Patients received ITCA 650 20 μg/day for 13 weeks, then 60 μg/day for 26 weeks. The primary end point was change in HbA1c at week 39. RESULTS Sixty patients were enrolled. At baseline, mean HbA1c was 10.8% (94.7 mmol/mol) and mean (± SD) duration of diabetes was 8.6 (± 5.3) years. At week 39, there was a mean reduction in HbA1c of −2.8% (−30.3 mmol/mol; P < 0.001 vs. baseline) and in body weight of −1.2 kg (P = 0.105), and 25% of patients achieved HbA1c 1c >10%.
- 4 January 2018
- Published by American Diabetes Association in Diabetes Care
- Vol. 41 (3) , 613-619
Clinical Impact of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Uncontrolled Type 2 Diabetes and Very High Baseline HbA1c: The FREEDOM-1 HBL (High Baseline) Study
OBJECTIVE ITCA 650 is a subdermal osmotic mini-pump that continuously delivers exenatide subcutaneously for 3–6 months. The efficacy, safety, and tolerability of ITCA 650 added to diet and exercise alone or combined with metformin, sulfonylurea, or thiazolidinedione monotherapy or a combination of these drugs was evaluated in poorly controlled patients with type 2 diabetes (T2D) who were ineligible for participation in a placebo-controlled study (FREEDOM-1) because of severe hyperglycemia (HbA1c >10% [86 mmol/mol]). RESEARCH DESIGN AND METHODS This 39-week, open-label, phase 3 trial enrolled patients aged 18–80 years with HbA1c >10% to ≤12% (86–108 mmol/mol) and BMI 25–45 kg/m2. Patients received ITCA 650 20 μg/day for 13 weeks, then 60 μg/day for 26 weeks. The primary end point was change in HbA1c at week 39. RESULTS Sixty patients were enrolled. At baseline, mean HbA1c was 10.8% (94.7 mmol/mol) and mean (± SD) duration of diabetes was 8.6 (± 5.3) years. At week 39, there was a mean reduction in HbA1c of −2.8% (−30.3 mmol/mol; P < 0.001 vs. baseline) and in body weight of −1.2 kg (P = 0.105), and 25% of patients achieved HbA1c 1c >10%.
- Open Access
- 14 December 2017
- Published by American Diabetes Association in Diabetes Care
- Vol. 41 (2) , 333-340
Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial
OBJECTIVE ITCA 650 (exenatide in osmotic mini-pump) continuously delivers exenatide subcutaneously for 3–6 months. Two doses of ITCA 650 were compared with placebo in patients with uncontrolled type 2 diabetes. RESEARCH DESIGN AND METHODS This 39-week, phase 3, double-blind, placebo-controlled trial randomized 460 patients aged 18–80 years with glycated hemoglobin (HbA1c) 7.5–10% [58–86 mmol/mol] 1:1:1 to placebo, ITCA 650 40 μg/day, or ITCA 650 60 μg/day. Primary end point was change in HbA1c at 39 weeks. RESULTS Least squares (LS) mean change from baseline HbA1c was −1.1% [−12.2 mmol/mol] and −1.2% [−13.2 mmol/mol] for ITCA 650 40 and 60 μg/day, respectively (P < 0.001 vs. placebo −0.1% [−1.3 mmol/mol]). In a prespecified analysis, greater HbA1c reductions occurred in patients not receiving sulfonylureas (SUs) vs. those receiving SUs (−1.7% vs. −1.2% [−18.6 and −13.1 mmol/mol]. At week 39, HbA1c P < 0.001 each dose vs. placebo). LS mean change from baseline body weight was −2.3 kg and −3.0 kg for ITCA 650 40 and 60 μg/day, respectively (P ≤ 0.015 vs. placebo −1.0 kg). Nausea was the most common adverse event (AE) and subsided over time. Discontinuation for gastrointestinal AEs occurred in 7.2% with ITCA and 1.3% with placebo. Most AEs associated with procedures to place and remove ITCA 650 were mild and transient. CONCLUSIONS ITCA 650 significantly reduced HbA1c and weight compared with placebo and was well tolerated in patients with uncontrolled type 2 diabetes on oral antidiabetes medications.
- 14 December 2017
- Published by American Diabetes Association in Diabetes Care
- Vol. 41 (2) , 333-340
Open AccessEfficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial
OBJECTIVE ITCA 650 (exenatide in osmotic mini-pump) continuously delivers exenatide subcutaneously for 3–6 months. Two doses of ITCA 650 were compared with placebo in patients with uncontrolled type 2 diabetes. RESEARCH DESIGN AND METHODS This 39-week, phase 3, double-blind, placebo-controlled trial randomized 460 patients aged 18–80 years with glycated hemoglobin (HbA1c) 7.5–10% [58–86 mmol/mol] 1:1:1 to placebo, ITCA 650 40 μg/day, or ITCA 650 60 μg/day. Primary end point was change in HbA1c at 39 weeks. RESULTS Least squares (LS) mean change from baseline HbA1c was −1.1% [−12.2 mmol/mol] and −1.2% [−13.2 mmol/mol] for ITCA 650 40 and 60 μg/day, respectively (P < 0.001 vs. placebo −0.1% [−1.3 mmol/mol]). In a prespecified analysis, greater HbA1c reductions occurred in patients not receiving sulfonylureas (SUs) vs. those receiving SUs (−1.7% vs. −1.2% [−18.6 and −13.1 mmol/mol]. At week 39, HbA1c P < 0.001 each dose vs. placebo). LS mean change from baseline body weight was −2.3 kg and −3.0 kg for ITCA 650 40 and 60 μg/day, respectively (P ≤ 0.015 vs. placebo −1.0 kg). Nausea was the most common adverse event (AE) and subsided over time. Discontinuation for gastrointestinal AEs occurred in 7.2% with ITCA and 1.3% with placebo. Most AEs associated with procedures to place and remove ITCA 650 were mild and transient. CONCLUSIONS ITCA 650 significantly reduced HbA1c and weight compared with placebo and was well tolerated in patients with uncontrolled type 2 diabetes on oral antidiabetes medications.
- 20 November 2017
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 20 (3) , 638-645
Treatment satisfaction with ITCA 650, a novel drug‐device delivering continuous exenatide, versus twice‐daily injections of exenatide in type 2 diabetics using metformin
Aims: To evaluate treatment satisfaction in patients with type 2 diabetes (T2D) not adequately controlled by metformin, randomized to ITCA 650 (continuous exenatide in osmotic mini‐pump) vs twice‐daily exenatide injections (Ex‐BID). Materials and methods: The Diabetes Medication Satisfaction Tool (DM‐SAT) was administered and assessments were made at baseline, Week 8 and Week 20 during a 24‐week open‐label phase 2 trial. In Stage I (Weeks 1‐12), 155 patients, comprising the ITT population, were randomized to 3 groups: ITCA 650 20 μg/day, ITCA 650 40 μg/day and Ex‐BID 10 μg BID. In Stage II (Weeks 13‐24), ITCA 650 groups were re‐randomized to either remain on the Stage I dose or receive a higher dose. Patients treated with Ex‐BID were randomized to 40 or 60 μg/day ITCA 650. Results: Patients using ITCA 650 reported significant increases in overall treatment satisfaction by Week 8 vs those using Ex‐BID ( P < .01), despite similar clinical efficacy and overall rates of nausea. During Stage II, further improvement in HbA1c and weight were seen after 3‐fold dose escalation of ITCA 650 and treatment satisfaction was maintained. When patients using Ex‐BID were switched to ITCA 650, treatment satisfaction increased and reached levels similar to those initially treated with ITCA 650. Neither GI side effects of nausea and/or vomiting, nor the procedure to sub‐dermally place ITCA 650, significantly impacted treatment satisfaction scores. Conclusion: ITCA 650 added to metformin for patients with T2D, and for those who switched to ITCA 650 from Ex‐BID, meaningfully improved glucose control and significantly increased overall treatment satisfaction.
- 20 November 2017
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 20 (3) , 638-645
Treatment satisfaction with ITCA 650, a novel drug‐device delivering continuous exenatide, versus twice‐daily injections of exenatide in type 2 diabetics using metformin
Aims: To evaluate treatment satisfaction in patients with type 2 diabetes (T2D) not adequately controlled by metformin, randomized to ITCA 650 (continuous exenatide in osmotic mini‐pump) vs twice‐daily exenatide injections (Ex‐BID). Materials and methods: The Diabetes Medication Satisfaction Tool (DM‐SAT) was administered and assessments were made at baseline, Week 8 and Week 20 during a 24‐week open‐label phase 2 trial. In Stage I (Weeks 1‐12), 155 patients, comprising the ITT population, were randomized to 3 groups: ITCA 650 20 μg/day, ITCA 650 40 μg/day and Ex‐BID 10 μg BID. In Stage II (Weeks 13‐24), ITCA 650 groups were re‐randomized to either remain on the Stage I dose or receive a higher dose. Patients treated with Ex‐BID were randomized to 40 or 60 μg/day ITCA 650. Results: Patients using ITCA 650 reported significant increases in overall treatment satisfaction by Week 8 vs those using Ex‐BID ( P < .01), despite similar clinical efficacy and overall rates of nausea. During Stage II, further improvement in HbA1c and weight were seen after 3‐fold dose escalation of ITCA 650 and treatment satisfaction was maintained. When patients using Ex‐BID were switched to ITCA 650, treatment satisfaction increased and reached levels similar to those initially treated with ITCA 650. Neither GI side effects of nausea and/or vomiting, nor the procedure to sub‐dermally place ITCA 650, significantly impacted treatment satisfaction scores. Conclusion: ITCA 650 added to metformin for patients with T2D, and for those who switched to ITCA 650 from Ex‐BID, meaningfully improved glucose control and significantly increased overall treatment satisfaction.
- Open Access
- 10 April 2013
- Published by Elsevier in Clinical Therapeutics
- Vol. 35 (5) , 634-645.e1
A Randomized, Open-Label, Multicenter, 4-Week Study to Evaluate the Tolerability and Pharmacokinetics of ITCA 650 in Patients With Type 2 Diabetes☆☆This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.
- 10 April 2013
- Published by Elsevier in Clinical Therapeutics
- Vol. 35 (5) , 634-645.e1
Open AccessA Randomized, Open-Label, Multicenter, 4-Week Study to Evaluate the Tolerability and Pharmacokinetics of ITCA 650 in Patients With Type 2 Diabetes☆☆This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited.